NVO News and Press, Novo Nordisk A/S From 05/28/24

2024-05-28 08:30:00 ET Summary Novo Nordisk stock has easily outperformed the market over the past year. Novo Nordisk's growth potential through its weight loss drugs is expanding. Competition from rivals like Eli Lilly and Amgen could impact demand and pricing dynamics in the...

2024-05-28 06:19:07 ET Summary Novo Nordisk reported great first quarter results again but free cash flow declined - in part due to high capital expenditures. At this point, we can expect the obesity market to continue growing with a high pace, but we should not ignore the increas...

2024-05-27 07:02:07 ET Summary Altimmune is developing an anti-obesity drug, Pemvidutide, that shows promising results in targeting fat mass and promoting weight loss. The obesity treatment market is expected to grow exponentially, reaching $77 billion by 2030, creating a signific...

2024-05-26 22:40:47 ET Summary Novo Nordisk is a Danish pharmaceutical company specializing in treatments for diabetes, obesity, and rare diseases. The company's main source of income comes from diabetes treatments, including insulin products and GLP-1 receptor agonists. Novo ...

2024-05-26 15:19:39 ET Summary Eli Lilly's shares reached new all-time highs after the company increased full-year revenue and EPS guidance. The company's growth is currently supply-constrained and the growth of tirzepatide in the near- and possibly medium-term should only be limi...

2024-05-26 13:36:00 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety The FTC Cracks Down On Novo Nordisk's Ozempic SA Asks: Is Eli Lilly or Novo ...

2024-05-26 06:53:00 ET With some promising clinical trial results in hand and more that could be on the way relatively soon, Amgen 's (NASDAQ: AMGN) latest attempt to develop a therapy for obesity is looking like it could be a contender for the crown that's currently jointly held by...

2024-05-25 09:15:00 ET Novo Nordisk (NYSE: NVO) has been a fantastic, market-beating stock to own for the past decade. Its 10-year return is an incredible 527%, which dwarfs the S&P 500 's 182% gain during the same period. But it wasn't until 2022 that the stock really took ...

2024-05-25 08:41:46 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Novo Nordisk once weekly insulin fails to get thu...

2024-05-25 07:00:00 ET Summary Buying stocks at record highs doesn't necessarily mean lower returns, and can actually lead to higher returns in the short term. Valuations matter, but the metric used to evaluate them is important. Cash-adjusted valuations provide a more accurate pi...